Andrew Worden, Chief Technology Officer, Vector BioMed
The most important technologies are and will be flexible platforms that speed development, efficiencies, and/or release. In the vector space, this involves a global viewpoint to improve therapeutic accessibility… focusing on cost, quality, and speed.
For example, there has been an increase in options for single-use components in all areas of biomanufacturing, and this has facilitated faster turnover between products, leading to more efficiency in providing vital materials for clinical and commercial use. There are now multiple options for single-use bioreactors, as well as chromatography flowpath and columns. Likewise, analytics have been improving to provide high-throughput platforms that allow for faster development and characterization by allowing an increase in sample analysis to understand processes and product better, and over a shorter period — or in parallel. Taken together, improvements like these support shorter timelines for product development, which leads to faster availability of critically needed therapeutics for patients.
For manufacturing and quality specifically, new tools and technologies that maintain efficiencies and streamline release without significantly impacting costs or timelines will create tangible speed to the clinic and beyond. There are service and tool providers that have alpha and beta products in the market now, but these are simply pieces of the puzzle. It will be specialized providers that offer and/or adopt the best solution for their workflow to be leveraged by clients that will have the greatest impact. Platform technologies, in general, have reached a precipice. The next several steps that are taken will define how the CDMO market functions in 2026 and beyond.
Particularly in the lentiviral vector–mediated gene therapy space, vector improvements to alter tropism and allow efficient modification of T cells without stimulation reagents is key to developing new therapies and possible in vivo strategies. Secondarily, more streamlined and efficient approaches to T cell isolation, as well as much shorter process durations, are driving better point-of-care manufacturing and treatment.
Lastly, in terms of market impact, there are only a few CDMOs that are thinking about true, vertical integration and commercial friendly at the same time. This will further fragment the CDMO landscape in the next 3–5 years, and rapid progress will be made in some areas while progress will be lost in other areas.
Anil Kane, Ph.D., Global Head of Technical & Scientific Affairs, Pharma Services, Thermo Fisher Scientific
The U.S. Food and Drug Administration (FDA) is actively supporting the advancement of pharmaceutical technologies through new initiatives like the Advanced Manufacturing Technologies (AMT) designation program and guidance documents on topics such as artificial intelligence (AI) in drug development and the use of digital health technologies (DHTs). The FDA is also encouraging investment in domestic manufacturing and facilitating the development of innovative technologies, such as cell lines and recombinant vaccine manufacturing.
The AMT designation program aims to improve drug manufacturing processes, enhance product quality and potentially reduce drug development time or increase drug supply, especially for critical drugs. That can include continuous manufacturing of oral solid dosage forms, as well as real-time release (RTR) technology, which offers potential benefits, such as improved product quality, reduced waste, lower costs and increased manufacturing flexibility. The FDA is also actively supporting the use of AI, machine learning (ML) and DHTs in drug development and manufacturing, which can contribute to improved efficiency and enhanced patient care. For example, DHTs include wearable devices, mobile health apps, and electronic records that enable telehealth and help empower individuals to manage their health more effectively.
For the CDMO market, investing in, implementing, and supporting the use of these advanced technologies can offer a competitive advantage. CDMOs also have the opportunity to lead in areas of application for predictive modeling, neural network, and ML in drug discovery, target identification, formulation and process development, stability predictions, and others. Adapting to this new paradigm and building infrastructure to support it is essential and could lead to stronger partnerships with pharma and biotech sponsors.
Chris Chen, Ph.D., Chief Executive Officer, WuXi Biologics
Digital technologies are poised to have a transformative impact on the CDMO industry in the future. These advancements will not only drive significantly greater efficiency and substantially higher throughput across our operations but will also revolutionize the way we interact and share data with our clients — ranging from project data management to invoicing. As a result, client experiences will be greatly enhanced, with communication becoming far more transparent and streamlined. For instance, our digitalized manufacturing solution system now enables clients to access real-time manufacturing data and maintain oversight throughout the entire process.
Randy Dyer, Vice President Marketing, Elegen
Among the most important new tools are those that collapse upstream timelines — delivering long, complex, sequence-verified DNA in days rather than weeks to decrease time to clinic. Cell-free platforms like ENFINIA™ DNA are making it possible to bypass cloning, linearization, and extensive purification, providing CDMOs with ready-to-use templates for mRNA, cell therapy, and gene therapy manufacturing.
By 2026 and beyond, we expect this drive a major shift in how CDMOs operate:
- Increased throughput: Faster DNA delivery means CDMOs can initiate more projects without adding infrastructure.
- Greater agility: Rapid iteration on constructs enables faster process development and adaptation to client needs.
- Supply chain resilience: Eliminating reliance on bacterial systems reduces bioburden, contamination risks, and production delays.
Ultimately, these platforms turn DNA from a rate-limiting step into a strategic enabler, giving CDMOs the capacity and flexibility to compete in an increasingly fast-moving therapeutics market.
Robert Hughes, Ph.D., R&D Fellow, Grace Services
The pharmaceutical industry’s commitment to rapidly delivering new therapies is driving a collaborative effort between drug sponsors and their CDMOs. Artificial intelligence (AI) and machine learning (ML) are vital tools enabling this partnership, helping CDMOs streamline development and manufacturing processes to contribute to faster overall timelines.
AI and ML offer substantial benefits across process and analytical development. In process development, we’ve seen these tools help optimize pharmaceutical production by swiftly analyzing extensive data sets, uncovering patterns, and identifying optimal conditions for yield, purity, and scalability. This reduces the reliance on lengthy, resource-heavy experimental trials, leading to enhanced efficiency and improved cost-effectiveness.
In analytical development, ML models facilitate the development of scientifically sound analytical methods for accurately assessing drug properties. These advanced analyses result in increased accuracy and reproducibility, supporting better decision-making and more robust quality assurance processes.
Additionally, AI and ML can help predict potential challenges early in development, minimizing risks associated with both process and analytical tasks. The opportunities for CDMOs to leverage machine learning in 2026 and beyond are exciting — potential benefits might be realized in the form of cost reductions through improved yields and faster cycle times, lower raw material expenses, accelerated timelines, improved impurity control, decreased risk of quality control delays, and a deeper understanding of production processes. Altogether, I think these advancements can not only speed up drug development but also improve product quality, reduce the risk of failures during commercial scale-up, and strengthen regulatory compliance.
Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories Limited
Continuous manufacturing (CM) has been a fad in the pharmaceutical industry for a while now, but we are seeing significant progress being made on this front. A wider range of molecules are being explored for development by smaller footprint CM platforms. CM will allow for improved quality control even as it enables more agile and scalable production with a reduced environmental footprint.
There are two aspects of digital/AI technology which we will see having more of an impact. One being the increasing use of AI/ML platforms across the value chain from molecule design and synthesis to process optimization, regulatory documentation, and quality control. We will see this leading to accelerated timelines, enhanced quality and reliability, increased efficiency, and cost reduction. Another element is the adoption of digital twins and simulations leading to enhanced collaboration between CDMOs and their customers, accelerated tech transfer, and better risk mitigation leading to lower failures.
The increased use of newer technologies will not just be bringing incremental changes but will force us to fundamentally rethink the whole pharmaceutical value chain.
Prasad Raje, Ph.D., Chief Executive Officer, LGM Pharma
One of the most impactful tools reshaping the CDMO landscape is AI. While economic volatility and regulatory shifts remain outside of our control, operational efficiency is something CDMOs can directly influence. From streamlining formulation development to enabling real-time process monitoring, AI has the potential to significantly reduce both timelines and costs. These efficiency gains not only ease financial pressure on CDMOs but also improve the viability of early-stage programs, increasing their chances of advancing to clinical and commercial phases.
On the consumer side, the rise of digital health platforms is transforming how therapies reach patients. The success of GLP-1 receptor agonists and GIP analogs has demonstrated how drugs originally developed for chronic conditions like diabetes can expand into broader lifestyle categories with mass-market appeal. Direct-to-consumer (DTC) platforms are facilitating this shift by allowing patients to access prescription therapies more quickly and without the traditional barriers to care. These digital channels are creating new demand patterns. For CDMOs, this means greater urgency to scale production rapidly and flexibly to meet the evolving needs of a more dynamic, digitally enabled market.
Jeff Goldman, General Manager, Ensorcell
CDMOs need flexibility in their platforms and technologies because they are dependent on projects advancing from early to late-stage manufacturing. It can be a hard call for a CDMO to standardize on a bioreactor or film because clients have often started development on a specific platform or using certain equipment or materials. It is not uncommon for a CDMO to purchase equipment particularly for a client process. So even when a platform is agreed upon between CDMO and client, the CDMO still has a lot of risk tied up in upfront investments in capital equipment and their facilities.
Low-cost, flexible, or universal equipment and materials (particularly upstream for cell culture) would have positive ripple effects across the board. This would lower the risk for CDMOs and reduce the investment needed by drug developers to translate their processes from the bench to process development and then into manufacturing. This is so important that Ensorcell is launching with a dedication to developing technologies with improved features and functionality that are also less expensive and more accessible to anyone developing drugs in house or at a CDMO.
The industry has hit an inflection point where the ability to lower the cost of goods sold without compromising quality needs to be prioritized for process equipment and consumables. We need the technologies used to manufacture drugs to meet all functional and regulatory requirements, but they should also be conceived with affordability in mind so safe, effective and affordable medications can get to the patients who need them.
Timothy Compton, Chief Strategy Officer, Alcami
Advancements in supply chain and enterprise resource planning (ERP) technologies are playing a pivotal role in enabling CDMOs to scale efficiently while maintaining operational excellence. ERP systems serve as integrated platforms that unify core business functions — such as manufacturing, procurement, inventory management, finance, and quality control — into a single source of truth. This integration enhances visibility, streamlines workflows, and supports data-driven decision-making across the organization.
At Alcami, we have implemented a comprehensive ERP solution to optimize resource planning, improve traceability, and ensure real-time coordination across departments. This system strengthens our ability to manage complex production schedules, maintain regulatory compliance, and respond quickly to client needs. As the CDMO landscape becomes increasingly competitive and capacity-constrained, robust ERP infrastructure will be essential for delivering reliable, scalable, and compliant services.
Tommy Duncan, Ph.D., Chief Business Officer, Touchlight
Recent advances in gene‐delivery technologies that enable cell‐specific targeting are driving a shift toward in vivo gene therapies. Improved lipid nanoparticle (LNP) formulations have enabled precise delivery to defined cell types, unlocking the potential for non-viral gene therapy approaches. Therefore, the demand for LNP and non-viral gene therapy manufacturing should be expected to grow significantly in 2026 and beyond. Additionally, improved lentiviral vector (LVV) pseudotyping has enhanced T cell targeting, paving the way for in vivo oncology programs, such as CAR-T therapies. This could result in a greater focus on LVV drug product manufacturing, which may present new safety and quality considerations. Together, these innovations are beginning to redirect efforts away from autologous, ex vivo CAR-T programs and toward in vivo strategies.
Nonetheless, continued growth in the number of ex vivo cell and gene therapies clinical programs is expected, given the nascence of in vivo gene therapy approaches. Future efforts in the ex vivo cell and gene therapy field will likely focus on optimization of manufacturing processes, simplification of workflows, development of allogeneic approaches, and targeting of more prevalent indications (e.g., autoimmune diseases).
Furthermore, recent advancements in genome editing technologies, such as CRISPR, have enabled highly precise modifications to correct faulty genes. While viral vectors remain a common delivery method for gene editing tools, emerging non-viral platforms, such as Touchlight’s enzymatic mbDNA™, offer promising alternatives that could streamline workflows and enhance safety profiles. As the field continues to evolve, we anticipate a significant increase in the development of ex vivo gene-edited cell therapies, and potentially in vivo gene-editing approaches, in 2026 and beyond.
Greater implementation of automation, as well as AI and ML, will also have a significant impact on the CDMO market in 2026 and beyond. The use of automation and robotics can improve precision, efficiency, and safety, where previously human error was an accepted risk. Robotics, such as liquid handlers, can handle repetitive tasks with high accuracy, particularly in aseptic manufacturing. ML will continue to allow for predictive analytics to model historical data and forecast future outcomes, which will lead to improved operational efficiency and decision-making.
Bill Humphries, Chief Executive Officer, MedPharm
There is a significant amount of discussion on AI and how it could help streamline operations and reduce time and costs for all stakeholders. We are in the early innings of AI and the potential for it to help with certain day-to-day CDMO services to expedite client deliverables is very attractive and something we are thinking about and working through. As a regulated industry, we need to take great care in evaluating and, in step with burgeoning regulation, eventually implementing AI in our day-to-day operations, if in fact a patient, client and company benefit can be clearly derived.
Michele Guasti, Global Product Manager, Terumo
As we look toward 2026 and beyond, several emerging tools and technology platforms are poised to significantly impact the CDMO market, driving innovation, efficiency, and once again patient-centric solutions.
One key area of development is the enhancement of molecule stability and reduction of interactions with container materials, which is critical for maintaining drug efficacy and safety, especially for biologics and complex formulations. This is particularly relevant as the industry sees a rise in high-viscosity and high-volume drugs, where combining pre-filled syringes with drug delivery devices is becoming essential to ensure accurate dosing and patient comfort.
Flexible fill and finish technologies, especially those utilizing ready-to-use (RTU) containers, are gaining traction for their ability to streamline operations, reduce contamination risks, and support faster time-to-market. These platforms offer scalability and adaptability across a wide range of primary packaging.
AI is increasingly integrated across the pharmaceutical value chain — from drug discovery and formulation optimization to predictive maintenance and personalized drug delivery. AI-driven insights are helping CDMOs improve decision-making, reduce development timelines, and enhance quality control.
The rise of connected drug delivery devices is revolutionizing patient engagement and adherence by enabling real-time monitoring and data collection. While these smart systems offer significant benefits — particularly in chronic disease management and home care settings — they also introduce cybersecurity risks, as their connectivity makes them potentially vulnerable to hacking and data breaches. By continuing to prioritize patient comfort, innovations in intradermal injection, needle design, and needle-free technologies are opening new doors for minimally invasive drug delivery across a wide range of treatments.
Finally, long-acting implants and depot formulations are gaining momentum, offering sustained release profiles that reduce dosing frequency and improve compliance — particularly in areas like oncology, endocrinology, and mental health. Together, these technologies are redefining the CDMO landscape, pushing the boundaries of what’s possible in drug development and delivery, and positioning the industry to better meet the evolving needs of patients and healthcare systems worldwide.
Yann D’Herve, Chief Executive Officer – CDMO, Cohance Lifesciences
Advanced therapies are essential if we are to address complex challenges, for example, in treating cancer. One major trend is the rise of advanced delivery systems, such as lipid nanoparticles (LNP) and antibody–drug conjugates (ADCs). The demand for advanced therapies is expected to continue to grow.
Some of the technologies being developed at Cohance Lifesciences are highly specialized, requiring CDMOs to manage small volume production in order to adequately support the commercialization of the new technologies.
In addition, some technologies, such as ADCs, are also extremely potent and require that CDMOs have the necessary containment systems to be able to handle highly potent materials safely.
Bastian Baur, Global Head of Digitalization, Adragos Pharma
In the generics CDMO market, the most important emerging tools are those that combine artificial intelligence (AI)-assisted decision support with validated digital manufacturing systems within a GxP-compliant framework. Rather than futuristic “self-driving” plants, the near-term impact will come from AI agents embedded into existing platforms, such as enterprise resource planning (ERP), manufacturing execution system (MES), quality management system (QMS), and laboratory information management system (LIMS,) helping operators, quality teams, and planners work faster and more accurately.
Examples include AI-powered deviation trend analysis, automated batch record review assistance, and predictive maintenance driven by integrated shopfloor data. These applications accelerate workflows, reduce human error, and support regulatory compliance without bypassing the necessary validation process.
By 2026, the CDMOs that will stand out are not those chasing experimental automation, but those strategically integrating AI into core, validated systems to achieve measurable gains in efficiency, release timelines, and cost competitiveness. In a highly price-sensitive generics market, the winners will be the ones that adopt AI in a way that is both operationally impactful and audit-ready, turning AI from a buzzword into a compliant productivity engine.
John Lee, Global Head of Cell & Gene Therapy, SK pharmteco
The most important new technologies currently transforming the CDMO market are AI and ML. These tools are not merely minor upgrades; they are fundamentally changing every phase of drug development and manufacturing.
Looking to 2026 and beyond, AI will enable CDMOs to be faster and more efficient partners. In drug development, AI already accelerates the identification of promising drug candidates, allowing CDMOs to shorten project timelines and lower costs for their clients. During manufacturing, AI-driven systems will monitor production processes in real-time to optimize quality and yield. The use of predictive maintenance, which analyzes sensor data to anticipate equipment failures, will minimize costly downtime and enhance overall operational efficiency.
Furthermore, AI-powered quality control through image recognition and data analytics will automate and enhance compliance with strict regulatory standards. Beyond the factory floor, AI will also improve demand forecasting and inventory management, strengthening the entire supply chain and making it more resilient to external disruptions. This integration of AI will transform CDMOs from service providers into agile, data-driven collaborators, providing a significant competitive advantage in a complex market.
Steven Facer, Senior Vice President, Global Sales and Marketing, Adare Pharma Solutions
One of the most important technology platforms emerging for CDMOs is 3D screen printing, which overcomes the limitations that held earlier 3D printing methods back. This additive cold-process technology applies a semi-solid paste in ultra-thin layers to construct dosage forms with precision and reproducibility.
Its biggest advantage lies in its flexibility. 3D screen printing enables multi-compartment tablets with immediate, extended, delayed, or sequential release all in a single dosage form. It can integrate multiple APIs with distinct pharmacokinetics, produce microtablets as small as 200 microns, and handle molecules that are difficult to compress using traditional methods. This opens new doors for customized dosing, taste masking, and patient-centric therapies.
Unlike most other forms of pharmaceutical 3D printing, the technology is scalable. The same process used to make just a few tablets for feasibility work can scale seamlessly to commercial production of up to 1.5 million units per day without process redesign.
As adoption expands in 2026 and beyond, 3D screen printing will help enable tailored, patient-centric therapies and streamline development-to-commercialization pathways, establishing CDMOs as central players in delivering personalized and precision medicines at scale.
Christian Seufert, Executive Committee Member and Head of Advanced Synthesis, Lonza
The CDMO sector is largely focused on developing and adopting new tools, such as AI and ML, and technology platforms to meet the growing demand for high-potency active pharmaceutical ingredients (HPAPIs). HPAPIs can pose substantial challenges for drug developers throughout the development and manufacturing life cycle, which include stringent safety protocols, advanced containment technologies, and specialized handling requirements.
Despite those challenges, the oncology category is driving substantial growth in the HPAPI market, fueled by the rising incidence of cancer and the need for more effective and more precisely targeted anticancer treatments. Many oncology drug innovators are recognizing the power of HPAPIs as crucial to the development of advanced anticancer therapies, particularly ADCs and bioconjugates. Today, roughly 70% to 80% of ADC manufacturing operations are outsourced due to the increased complexity of handling cytotoxic substances, which requires thorough knowledge and experience in manufacturing and scaling these molecules.
As CDMOs respond to growing demand for innovative therapies, investments in AI technologies are accelerating, particularly in drug discovery and process optimization for HPAPIs. Lonza’s Design2Optimize™ platform is one such innovation, created to support the efficient development and manufacture of small-molecule APIs. While Design2Optimize™ is a standalone offering, it can be enhanced through complementary services, such as Lonza’s AI-Enabled Route Scouting, leveraging proprietary supply chain databases, process R&D expertise, and computer-aided synthesis planning, and High-Throughput Experimentation (HTE), which enables rapid screening of reaction conditions. These services, used individually or in combination, help streamline timelines and improve process efficiency.
In parallel with AI-driven process optimization, continuous flow chemistry is becoming increasingly prominent as a strategic platform for small molecule development and manufacturing. Continuous flow enables enhanced control over reaction conditions, improved safety for hazardous transformations, and greater scalability for complex chemistries. By integrating continuous flow into early development, drug developers can benefit from accelerated timelines, reduced waste, and improved reproducibility, particularly for challenging reactions that benefit from precise thermal and mixing control. Lonza offers this approach, which also complements our Design2Optimize™ platform and supports the efficient transition from lab-scale to commercial production, reinforcing our commitment to innovation and operational excellence.
Looking specifically at ADCs, it is vital to continue innovating across the entire drug development process to unlock early innovation, enabling the rise of more diverse and complex ADCs. Through our Bioconjugation Toolbox, comprising a variety of conjugation technologies, linkers, and payloads, we help drive the next wave of innovation in ADCs by accelerating timelines and reducing complexity on the journey to commercialization.
Kayleigh Coxon, Business Analyst, Business Intelligence and Insights, FUJIFILM Biotechnologies
In 2026, groundbreaking advancements in process intensification, analytics, and next-gen vector platforms will significantly shape the CDMO market, enabling growth and innovation.
Process intensification, such as transitioning from fed-batch to perfusion and continuous downstream processing (DSP), promises smaller footprint and quicker turnarounds, which are transformative for efficiency. CDMOs like FUJIFILM Biotechnologies that provide connected DSP solutions can effectively alleviate downstream bottlenecks for its partners.
Advancements in analytical and digital technologies, including multi-attribute methods (MAM) and digital twins, are accelerating tech transfers and enhancing precision. As the regulatory landscape evolves, CDMOs investing in digitalization, like FUJIFILM Biotechnologies, will be able to offer faster, more reliable services to customers.
Innovations in next-gen vector platforms, particularly in suspension AAV and cell-free mRNA transcription, will enable CDMOs to scale diverse biotech projects effectively. FUJIFILM Biotechnologies’ commitment to innovation will help drive the industry forward.
Michael Nonnenmacher, Ph.D., Director of Differentiating Technologies, Evonik
In the CDMO market, digital solutions are increasingly important. These tools are accelerating development timelines and improving implementation efficiency for new products. The integration of process analytical tools (PAT) and closed-loop feedback systems will significantly improve process robustness at scale, enabling real-time monitoring and adjustments during production.
Advancements in automation and artificial intelligence are also helping CDMOs to streamline operations, reduce variability, and optimize resource use. Meanwhile, cloud-based platforms are improving data transparency and collaboration across the supply chain, allowing for faster, more informed decision-making and more agile responses to market shifts.
As these technologies mature, they are expected to redefine the competitive landscape of the CDMO market by enabling greater flexibility, reliability, and speed. At Evonik, innovation in chemical process development is a strategic priority. We are exploring the use of machine learning, 3D printing, and advanced modeling to optimize reaction conditions and reactor design — efforts that are already helping to reduce development cycles and improve scalability.
Looking ahead to 2026 and beyond, these technological innovations will not only enhance operational efficiencies but also foster greater flexibility in responding to customer needs, ultimately reshaping the competitive landscape of the CDMO market.
Franco Negron, Chief Executive Officer, Simtra BioPharma Solutions
Without a doubt, AI and ML are changing drug development and manufacturing and will continue to do so. From monitoring the manufacturing line to improving supply chain resilience, AI and ML are playing an increasingly important role in drug manufacturing. These technologies may also impact capacity needs of CDMOs as they accelerate the identification of drug candidates and also help optimize drug formulations, which have the potential to accelerate the pace of drug development and increase demand for development services.
Matthew Bio, Ph.D., Chief Scientific Officer, Cambrex
The demand for sustainable and scalable methods for the manufacture of peptides and oligonucleotides has driven the development of liquid-phase synthesis technology to supplement or displace solid-phase where large volumes and sustainability pressures make scale-up challenging. Liquid-phase peptide/oligonucleotide synthesis (LPPS/LPOS) enables traditional small molecule capacity to be applied and realize the economies of scale typical of synthetic drug substance manufacturing.
Nanofiltration technology, particularly using membranes compatible with organic solvents is an important technology for the purification of large, complex synthetic modalities. Nanofiltration is augmenting LPPS/LPOS as a purification technique to reduce the reliance on inefficient chromatographic purification. LPPS/LPOS and nanofiltration are driving significant improvements in the efficiency and economics of tides manufacturing and will be critical to ensuring supply of large volume peptide and oligonucleotide therapeutics.
Russell Miller, Vice President of Global Sales & Marketing, Enzene
Truly continuous biomanufacturing has already eliminated contamination control as a day-to-day concern, and in my opinion, 2026 will see its adoption deliver so many important benefits in terms of speeding development, reducing complexity, waste, reducing the impact of biomanufacturing on the environmental and, of course, cost. It’s important that CDMOs have a focus on continuous innovation, but also on ‘open’ architecture that allows for upgradability. With their guidance for continuous manufacturing for biologics, regulators have clearly signalled their openness to doing things differently and better. The regulatory environment is asking us to consider new manufacturing techniques. You would not consider starting an oral dose manufacturing plant without continuous manufacturing in place, and even as a relative newcomer the industry now has that same expectation for biomanufacturing. Through continuous manufacturing a plant that costs a couple of million dollars can outperform one that cost a billion dollars, and that’s important for the CDMO market and its clients.
